Literature DB >> 20699475

The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development.

Faruk Ramadani1, Daniel J Bolland, Fabien Garcon, Juliet L Emery, Bart Vanhaesebroeck, Anne E Corcoran, Klaus Okkenhaug.   

Abstract

B cell development is controlled by a series of checkpoints that ensure that the immunoglobulin (Ig)-encoding genes produce a functional B cell receptor (BCR) and antibodies. As part of this process, recombination-activating gene (Rag) proteins regulate the in-frame assembly of the Ig-encoding genes. The BCR consists of Ig proteins in complex with the immunoreceptor tyrosine-based activation motif (ITAM)-containing Igalpha and Igbeta chains. Whereas the activation of the tyrosine kinases Src and Syk is essential for BCR signaling, the pathways that act downstream of these kinases are incompletely defined. Previous work has revealed a key role for the p110delta isoform of phosphatidylinositol 3-kinase (PI3K) in agonist-induced BCR signaling; however, early B cell development and mature B cell survival, which depend on agonist-independent or "tonic" BCR signaling, are not substantially affected by a deficiency in p110delta. Here, we show that p110alpha, but not p110beta, compensated in the absence of p110delta to promote early B cell development in the bone marrow and B cell survival in the spleen. In the absence of both p110alpha and p110delta activities, pre-BCR signaling failed to suppress the production of Rag proteins and to promote developmental progression of B cell progenitors. Unlike p110delta, however, p110alpha did not contribute to agonist-induced BCR signaling. These studies indicate that either p110alpha or p110delta can mediate tonic signaling from the BCR, but only p110delta can contribute to antigen-dependent activation of B cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20699475      PMCID: PMC3540743          DOI: 10.1126/scisignal.2001104

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  54 in total

1.  Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase.

Authors:  Yuichi Aiba; Megumi Kameyama; Tetsuo Yamazaki; Thomas F Tedder; Tomohiro Kurosaki
Journal:  Blood       Date:  2007-11-19       Impact factor: 22.113

Review 2.  Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling.

Authors:  Sebastian Herzog; Michael Reth; Hassan Jumaa
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

Review 3.  Fine tuning the immune response with PI3K.

Authors:  David A Fruman; Georges Bismuth
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

4.  Transcription of productive and nonproductive VDJ-recombined alleles after IgH allelic exclusion.

Authors:  Janssen Daly; Steve Licence; Aikaterini Nanou; Geoff Morgan; Inga-Lill Mårtensson
Journal:  EMBO J       Date:  2007-09-06       Impact factor: 11.598

5.  Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration.

Authors:  Mariona Graupera; Julie Guillermet-Guibert; Lazaros C Foukas; Li-Kun Phng; Robert J Cain; Ashreena Salpekar; Wayne Pearce; Stephen Meek; Jaime Millan; Pedro R Cutillas; Andrew J H Smith; Anne J Ridley; Christiana Ruhrberg; Holger Gerhardt; Bart Vanhaesebroeck
Journal:  Nature       Date:  2008-04-30       Impact factor: 49.962

6.  The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma.

Authors:  Julie Guillermet-Guibert; Katja Bjorklof; Ashreena Salpekar; Cristiano Gonella; Faruk Ramadani; Antonio Bilancio; Stephen Meek; Andrew J H Smith; Klaus Okkenhaug; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-10       Impact factor: 11.205

7.  Foxo1 directly regulates the transcription of recombination-activating genes during B cell development.

Authors:  Rupesh H Amin; Mark S Schlissel
Journal:  Nat Immunol       Date:  2008-05-11       Impact factor: 25.606

8.  The effect of deleting p110delta on the phenotype and function of PTEN-deficient B cells.

Authors:  Michelle L Janas; Daniel Hodson; Zania Stamataki; Sue Hill; Katie Welch; Laure Gambardella; Lloyd C Trotman; Pier Paolo Pandolfi; Elena Vigorito; Martin Turner
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

9.  Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation.

Authors:  Hart S Dengler; Gisele V Baracho; Sidne A Omori; Shane Bruckner; Karen C Arden; Diego H Castrillon; Ronald A DePinho; Robert C Rickert
Journal:  Nat Immunol       Date:  2008-11-02       Impact factor: 25.606

10.  CCR7 ligands control basal T cell motility within lymph node slices in a phosphoinositide 3-kinase-independent manner.

Authors:  François Asperti-Boursin; Eliana Real; Georges Bismuth; Alain Trautmann; Emmanuel Donnadieu
Journal:  J Exp Med       Date:  2007-05-07       Impact factor: 14.307

View more
  93 in total

Review 1.  Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation.

Authors:  G V Baracho; A V Miletic; S A Omori; M H Cato; R C Rickert
Journal:  Curr Opin Immunol       Date:  2011-02-01       Impact factor: 7.486

2.  The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Authors:  R Thijssen; J Ter Burg; G G W van Bochove; M F M de Rooij; A Kuil; M H Jansen; T W Kuijpers; J W Baars; A Virone-Oddos; M Spaargaren; C Egile; M H J van Oers; E Eldering; M J Kersten; A P Kater
Journal:  Leukemia       Date:  2015-09-04       Impact factor: 11.528

Review 3.  Molecules in medicine mini-review: isoforms of PI3K in biology and disease.

Authors:  Bart Vanhaesebroeck; Maria A Whitehead; Roberto Piñeiro
Journal:  J Mol Med (Berl)       Date:  2015-12-10       Impact factor: 4.599

Review 4.  Phosphatidylinositol 3 Kinase δ Inhibitors: Present and Future.

Authors:  Jennifer R Brown
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

Review 5.  Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.

Authors:  Markus Müschen
Journal:  Blood       Date:  2015-04-15       Impact factor: 22.113

Review 6.  Targeting the B cell receptor pathway in chronic lymphocytic leukemia.

Authors:  Matthew S Davids; Jennifer R Brown
Journal:  Leuk Lymphoma       Date:  2012-12

7.  The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.

Authors:  Laia Rosich; Ifigènia Saborit-Villarroya; Mónica López-Guerra; Sílvia Xargay-Torrent; Arnau Montraveta; Marta Aymerich; Neus Villamor; Elias Campo; Patricia Pérez-Galán; Gaël Roué; Dolors Colomer
Journal:  Haematologica       Date:  2013-07-12       Impact factor: 9.941

8.  c-Myb Coordinates Survival and the Expression of Genes That Are Critical for the Pre-BCR Checkpoint.

Authors:  Shawn P Fahl; Andrea R Daamen; Rowena B Crittenden; Timothy P Bender
Journal:  J Immunol       Date:  2018-04-13       Impact factor: 5.422

Review 9.  Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Blood       Date:  2012-08-08       Impact factor: 22.113

10.  Conditional Disruption of Raptor Reveals an Essential Role for mTORC1 in B Cell Development, Survival, and Metabolism.

Authors:  Terri N Iwata; Julita A Ramírez; Mark Tsang; Heon Park; Daciana H Margineantu; David M Hockenbery; Brian M Iritani
Journal:  J Immunol       Date:  2016-08-12       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.